European Archives - Page 118 of 1345 - European Medical Journal

Monoclonal Antibody Cuts Bleeding Risk in Atrial Fibrillation with Kidney Disease

Abelacimab reduces bleeding risk in atrial fibrillation patients, even with kidney disease, study finds.

From Imaging to Advocacy: Interview with David E. Winchester

The technology that I use most frequently is coronary flow reserve combined with PET perfusion imaging and coronary artery calcium scoring…

10 Sep 2025

Avelumab 1L Maintenance in aUC: Insights from 5000+ Real-World Patients

Urothelial carcinoma (UC), a prevalent cancer affecting the urinary tract, often progresses to an advanced, terminal…

Informed Formula Choices for Infants with CMA

This symposium review article discusses the latest European guidelines for the diagnosis and treatment of cow’s milk allergy in young…

EMJ Allergy & Immunology 10 [Supplement 5] 2025

Hear from experts at ESPHGAN 2025 at a Nestlé Nutrition Institute-sponsored symposium, which explores key considerations for making…

Lilly's TuneLab to share AI models with small biotechs

Lilly has launched TuneLab, giving biotech companies access to AI-powered drug discovery models based on over £1bn in research investment.

Corrigendum: Diabetic Ketoacidosis in Pregnancy: An Overview of Pathophysiology, Management, and Pregnancy Outcomes

Central Lung Tumour Location Tied to Worse Outcomes Post-Surgery

Central tumour location linked to worse survival in lung cancer, suggesting need for closer post-operation monitoring.

Sara Tolaney

Onc Now: Episode 25: From Trials to Treatment in Breast Cancer Care

Sara Tolaney shares insights on breast cancer care, including her research on CDK4/6 inhibitors and exploring ways to de-escalate treatment.

Prognostic Power of Detecting Minimal Residual Disease in Ovarian Cancer

Minimal residual disease (MRD) is a major barrier to curing advanced ovarian cancer, even in patients who appear disease-free after initial therapy. A recent study of 95 patients showed that MRD detected through second-look laparoscopy or circulating tumor DNA strongly predicted shorter progression-free and overall survival.